110 related articles for article (PubMed ID: 21566342)
21. Induction of UGT1A1 and CYP2B6 by an antimitogenic factor in HepG2 cells is mediated through suppression of cyclin-dependent kinase 2 activity: cell cycle-dependent expression.
Sugatani J; Osabe M; Kurosawa M; Kitamura N; Ikari A; Miwa M
Drug Metab Dispos; 2010 Jan; 38(1):177-86. PubMed ID: 19797611
[TBL] [Abstract][Full Text] [Related]
22. Exploring the possible metabolism mediated interaction of Glycyrrhiza glabra extract with CYP3A4 and CYP2D6.
Pandit S; Ponnusankar S; Bandyopadhyay A; Ota S; Mukherjee PK
Phytother Res; 2011 Oct; 25(10):1429-34. PubMed ID: 21351298
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of in vitro cytochrome P450 induction and inhibition activity of deoxyelephantopin, a sesquiterpene lactone from Elephantopus scaber L.
Koe XF; Lim EL; Seah TC; Amanah A; Wahab HA; Adenan MI; Sulaiman SF; Tan ML
Food Chem Toxicol; 2013 Oct; 60():98-108. PubMed ID: 23876819
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis.
Lobenhofer EK; Huper G; Iglehart JD; Marks JR
Cell Growth Differ; 2000 Feb; 11(2):99-110. PubMed ID: 10714766
[TBL] [Abstract][Full Text] [Related]
25. In vitro inhibition of methadone and oxycodone cytochrome P450-dependent metabolism: reversible inhibition by H2-receptor agonists and proton-pump inhibitors.
Moody DE; Liu F; Fang WB
J Anal Toxicol; 2013 Oct; 37(8):476-85. PubMed ID: 23857299
[TBL] [Abstract][Full Text] [Related]
26. Regulation of endothelial nitric-oxide synthase activity through phosphorylation in response to epoxyeicosatrienoic acids.
Jiang JG; Chen RJ; Xiao B; Yang S; Wang JN; Wang Y; Cowart LA; Xiao X; Wang DW; Xia Y
Prostaglandins Other Lipid Mediat; 2007 Jan; 82(1-4):162-74. PubMed ID: 17164144
[TBL] [Abstract][Full Text] [Related]
27. Evidence for the activation of organophosphate pesticides by cytochromes P450 3A4 and 2D6 in human liver microsomes.
Sams C; Mason HJ; Rawbone R
Toxicol Lett; 2000 Aug; 116(3):217-21. PubMed ID: 10996483
[TBL] [Abstract][Full Text] [Related]
28. Effects of diltiazem, a moderate inhibitor of CYP3A4, on the pharmacokinetics of tamsulosin in different CYP2D6 genotypes.
Byeon JY; Lee YJ; Kim YH; Kim SH; Lee CM; Bae JW; Jang CG; Lee SY; Choi CI
Arch Pharm Res; 2018 May; 41(5):564-570. PubMed ID: 29728928
[TBL] [Abstract][Full Text] [Related]
29. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes.
Lalovic B; Phillips B; Risler LL; Howald W; Shen DD
Drug Metab Dispos; 2004 Apr; 32(4):447-54. PubMed ID: 15039299
[TBL] [Abstract][Full Text] [Related]
30. In vitro study on the involvement of CYP1A2, CYP2D6 and CYP3A4 in the metabolism of haloperidol and reduced haloperidol.
Pan L; Belpaire FM
Eur J Clin Pharmacol; 1999 Oct; 55(8):599-604. PubMed ID: 10541779
[TBL] [Abstract][Full Text] [Related]
31. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
Brown HS; Galetin A; Hallifax D; Houston JB
Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
[TBL] [Abstract][Full Text] [Related]
32. Cytotoxicity, antioxidant activity and an effect on CYP3A4 and CYP2D6 of Mutellina purpurea L. extracts.
Sieniawska E; Baj T; Dudka J; Gieroba R; Swiatek L; Rajtar B; Glowniak K; Polz-Dacewicz M
Food Chem Toxicol; 2013 Feb; 52():188-92. PubMed ID: 23182739
[TBL] [Abstract][Full Text] [Related]
33. A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone.
Potkin SG; Preskorn S; Hochfeld M; Meng X
J Clin Psychopharmacol; 2013 Feb; 33(1):3-10. PubMed ID: 23277250
[TBL] [Abstract][Full Text] [Related]
34. The interactions of a selective protein kinase C beta inhibitor with the human cytochromes P450.
Ring BJ; Gillespie JS; Binkley SN; Campanale KM; Wrighton SA
Drug Metab Dispos; 2002 Sep; 30(9):957-61. PubMed ID: 12167559
[TBL] [Abstract][Full Text] [Related]
35. Exploration of catalytic properties of CYP2D6 and CYP3A4 through metabolic studies of levorphanol and levallorphan.
Bonn B; Masimirembwa CM; Castagnoli N
Drug Metab Dispos; 2010 Jan; 38(1):187-99. PubMed ID: 19797609
[TBL] [Abstract][Full Text] [Related]
36. Identification of human cytochrome P450 enzymes involved in the metabolism of IN-1130, a novel activin receptor-like kinase-5 (ALK5) inhibitor.
Kim YW; Kim YK; Kim DK; Sheen YY
Xenobiotica; 2008 May; 38(5):451-64. PubMed ID: 18421620
[TBL] [Abstract][Full Text] [Related]
37. Characterization of human cytochrome P450s involved in the bioactivation of clozapine.
Dragovic S; Gunness P; Ingelman-Sundberg M; Vermeulen NP; Commandeur JN
Drug Metab Dispos; 2013 Mar; 41(3):651-8. PubMed ID: 23297297
[TBL] [Abstract][Full Text] [Related]
38. Development of Caco-2 cells-based gene reporter assays and evaluation of herb-drug interactions involving CYP3A4 and CYP2D6 gene expression.
Feltrin C; Brambila PF; Simões CMO
Chem Biol Interact; 2019 Apr; 303():79-89. PubMed ID: 30772286
[TBL] [Abstract][Full Text] [Related]
39. In vitro studies on quetiapine metabolism using the substrate depletion approach with focus on drug-drug interactions.
Hasselstrøm J; Linnet K
Drug Metabol Drug Interact; 2006; 21(3-4):187-211. PubMed ID: 16841513
[TBL] [Abstract][Full Text] [Related]
40. Polysaccharide peptides from Coriolus versicolor competitively inhibit model cytochrome P450 enzyme probe substrates metabolism in human liver microsomes.
Yeung JH; Or PM
Phytomedicine; 2012 Mar; 19(5):457-63. PubMed ID: 22305191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
